PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions

Leuk Lymphoma. 2019 Jan;60(1):262-264. doi: 10.1080/10428194.2018.1471602. Epub 2018 Jun 22.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Cells / drug effects*
  • Bone Marrow Cells / pathology
  • Cell Line, Tumor
  • Coculture Techniques
  • DNA Breaks, Double-Stranded / drug effects
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Imatinib Mesylate / pharmacology
  • Imatinib Mesylate / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Mice
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / pathology
  • Phthalazines / pharmacology
  • Phthalazines / therapeutic use
  • Poly (ADP-Ribose) Polymerase-1 / antagonists & inhibitors
  • Tumor Microenvironment / drug effects
  • Tumor Microenvironment / genetics
  • Xenograft Model Antitumor Assays

Substances

  • Phthalazines
  • Imatinib Mesylate
  • talazoparib
  • PARP1 protein, human
  • Poly (ADP-Ribose) Polymerase-1